Other Species / Isoforms
  SPRY2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S7-p
_MEARAQsGNGsQPL
1 3
SPRY2 (human) _MEARAQsGNGsQPL S7-p
SPRY2 (mouse) _MEARAQSGNGsQPL S7
SPRY2 (rat) _MEARAQSGSGSQPL S7
S11-p
RAQsGNGsQPLLQtP
0 2
SPRY2 (human) RAQsGNGsQPLLQtP S11-p
SPRY2 (mouse) RAQSGNGsQPLLQtA S11-p
SPRY2 (rat) RAQSGSGSQPLLQSP S11
T17-p
GsQPLLQtPRDGGRQ
0 4
SPRY2 (human) GsQPLLQtPRDGGRQ T17-p
SPRY2 (mouse) GsQPLLQtAHDsGRQ T17-p
SPRY2 (rat) GSQPLLQSPHDSGRQ S17
G21
LLQtPRDGGRQRGEP
0 1
SPRY2 (human) LLQtPRDGGRQRGEP G21
SPRY2 (mouse) LLQtAHDsGRQRGEP S21-p
SPRY2 (rat) LLQSPHDSGRQRGEP S21
S42-p
TQQVHVLsLDQIRAI
1 2
SPRY2 (human) TQQVHVLsLDQIRAI S42-p
SPRY2 (mouse) TQQVHVLSLDQIRAI S42
SPRY2 (rat) TQQVHVLSLDQIRAI S42
Y55-p
AIRNTNEytEGPTVV
Upstream
Downstream
10 93
Effects on Modified Protein
  • activity, induced
  • activity, inhibited
  • molecular association, regulation
  • phosphorylation
  • protein degradation
Effects on Biological Processes:
  • cell differentiation, altered
  • transcription, altered
Kinase, in vitro:
  • Src (human)
Putative in vivo kinases:
  • Src (human)
Regulatory protein:
  • FGFR1 (human)
  • Src (human)
Treatment
  • EGF
  • FGF2
  • SU6656
SPRY2 (human) AIRNTNEytEGPTVV Y55-p
SPRY2 (mouse) AIRNTNEyTEGPTVV Y55-p
SPRY2 (rat) AIRNTNEYTEGPTVV Y55
T56-p
IRNTNEytEGPTVVP
0 1
SPRY2 (human) IRNTNEytEGPTVVP T56-p
SPRY2 (mouse) IRNTNEyTEGPTVVP T56
SPRY2 (rat) IRNTNEYTEGPTVVP T56
T75-p
KPAPRPStQHkHERL
Upstream
Downstream
2 0
Effects on Modified Protein
  • activity, inhibited
Kinase, in vitro:
  • DYRK1A (human)
Putative in vivo kinases:
  • DYRK1A (human)
Treatment
  • harmine
  • norharmane
SPRY2 (human) KPAPRPStQHkHERL T75-p
SPRY2 (mouse) KPAPRPSTQHKHERL T75
SPRY2 (rat) KPAPRPSTQHKHERL T75
K78-m1
PRPStQHkHERLHGL
0 1
SPRY2 (human) PRPStQHkHERLHGL K78-m1
SPRY2 (mouse) PRPSTQHKHERLHGL K78
SPRY2 (rat) PRPSTQHKHERLHGL K78
S97-p
QPPRLQHsQVHSSAR
0 2
SPRY2 (human) QPPRLQHsQVHSSAR S97-p
SPRY2 (mouse) QPPRLQPSQVHSSRA S97
SPRY2 (rat) QPPRLQPTQVHSSRA T97
S112-p
APLSRSIsTVssGsR
Upstream
Downstream
4 3
Effects on Modified Protein
  • molecular association, regulation
  • protein stabilization
  • ubiquitination
Kinase, in vitro:
  • Mnk1 (human)
Putative in vivo kinases:
  • Mnk1 (human)
  • Mnk2 (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • CGP57380
  • EGF
  • FGF2
  • okadaic_acid
SPRY2 (human) APLSRSIsTVssGsR S112-p
SPRY2 (mouse) APLSRSIsTVsSGSR S111-p
SPRY2 (rat) AALSRSVSTVSSGSR S111
S115-p
SRSIsTVssGsRSsT
Upstream
1 3
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • FGF2
  • okadaic_acid
SPRY2 (human) SRSIsTVssGsRSsT S115-p
SPRY2 (mouse) SRSIsTVsSGSRSSt S114-p
SPRY2 (rat) SRSVSTVSSGSRSST S114
S116-p
RSIsTVssGsRSsTR
0 1
SPRY2 (human) RSIsTVssGsRSsTR S116-p
SPRY2 (mouse) RSIsTVsSGSRSStR S115
SPRY2 (rat) RSVSTVSSGSRSSTR S115
S118-p
IsTVssGsRSsTRtS
0 1
SPRY2 (human) IsTVssGsRSsTRtS S118-p
SPRY2 (mouse) IsTVsSGSRSStRTS S117
SPRY2 (rat) VSTVSSGSRSSTRTS S117
S121-p
VssGsRSsTRtSTSs
Upstream
Downstream
3 1
Effects on Modified Protein
  • molecular association, regulation
  • protein stabilization
  • ubiquitination
Kinase, in vitro:
  • Mnk1 (human)
Putative in vivo kinases:
  • Mnk1 (human)
  • Mnk2 (human)
Treatment
  • CGP57380
  • EGF
SPRY2 (human) VssGsRSsTRtSTSs S121-p
SPRY2 (mouse) VsSGSRSStRTSTSS S120
SPRY2 (rat) VSSGSRSSTRTSTSS S120
T122
ssGsRSsTRtSTSsS
0 1
SPRY2 (human) ssGsRSsTRtSTSsS T122
SPRY2 (mouse) sSGSRSStRTSTSSS T121-gl
SPRY2 (rat) SSGSRSSTRTSTSSS T121
T124-p
GsRSsTRtSTSsSSs
0 1
SPRY2 (human) GsRSsTRtSTSsSSs T124-p
SPRY2 (mouse) GSRSStRTSTSSSSS T123
SPRY2 (rat) GSRSSTRTSTSSSSS T123
S128-p
sTRtSTSsSSsEQRL
0 1
SPRY2 (human) sTRtSTSsSSsEQRL S128-p
SPRY2 (mouse) StRTSTSSSSSEQRL S127
SPRY2 (rat) STRTSTSSSSSEQRL S127
S131-p
tSTSsSSsEQRLLGs
0 1
SPRY2 (human) tSTSsSSsEQRLLGs S131-p
SPRY2 (mouse) TSTSSSSSEQRLLGP S130
SPRY2 (rat) TSTSSSSSEQRLLGS S130
S138-p
sEQRLLGssFssGPV
Upstream
0 2
Treatment
  • FGF2
SPRY2 (human) sEQRLLGssFssGPV S138-p
SPRY2 (mouse) SEQRLLGPSFSHGPA P137
SPRY2 (rat) SEQRLLGSSFSPGPA S137
S139-p
EQRLLGssFssGPVA
Upstream
0 6
Treatment
  • metastatic potential
SPRY2 (human) EQRLLGssFssGPVA S139-p
SPRY2 (mouse) EQRLLGPSFSHGPAA S138
SPRY2 (rat) EQRLLGSSFSPGPAV S138
S141-p
RLLGssFssGPVADG
1 3
SPRY2 (human) RLLGssFssGPVADG S141-p
SPRY2 (mouse) RLLGPSFSHGPAAAD S140
SPRY2 (rat) RLLGSSFSPGPAVDG S140
S142-p
LLGssFssGPVADGI
0 3
SPRY2 (human) LLGssFssGPVADGI S142-p
SPRY2 (mouse) LLGPSFSHGPAAADG H141
SPRY2 (rat) LLGSSFSPGPAVDGI P141
S156-p
IIRVQPKsELkPGEL
Upstream
0 1
Treatment
  • FGF2
SPRY2 (human) IIRVQPKsELkPGEL S156-p
SPRY2 (mouse) IIRVQPKSELKPGDV S156
SPRY2 (rat) IIRVQPKSELKSGEL S155
K159-ub
VQPKsELkPGELkPL
0 1
SPRY2 (human) VQPKsELkPGELkPL K159-ub
SPRY2 (mouse) VQPKSELKPGDVkPL K159
SPRY2 (rat) VQPKSELKSGELKPL K158
K164-ub
ELkPGELkPLskEDL
0 2
SPRY2 (human) ELkPGELkPLskEDL K164-ub
SPRY2 (mouse) ELKPGDVkPLSKDDL K164-ub
SPRY2 (rat) ELKSGELKPLSRDDL K163
S167-p
PGELkPLskEDLGLH
Upstream
1 4
Treatment
  • FGF2
SPRY2 (human) PGELkPLskEDLGLH S167-p
SPRY2 (mouse) PGDVkPLSKDDLGLH S167
SPRY2 (rat) SGELKPLSRDDLGLH S166
K168-ub
GELkPLskEDLGLHA
0 1
SPRY2 (human) GELkPLskEDLGLHA K168-ub
SPRY2 (mouse) GDVkPLSKDDLGLHA K168
SPRY2 (rat) GELKPLSRDDLGLHA R167
Y176-p
EDLGLHAyRCEDCGK
Upstream
0 1
Treatment
  • FGF2
SPRY2 (human) EDLGLHAyRCEDCGK Y176-p
SPRY2 (mouse) DDLGLHAYRCEDCGK Y176
SPRY2 (rat) DDLGLHAYRCEDCGK Y175
T190-p
KCKCKECtyPRPLPs
Upstream
0 1
Treatment
  • FGF2
SPRY2 (human) KCKCKECtyPRPLPs T190-p
SPRY2 (mouse) KCKCKECTYPRPLPS T190
SPRY2 (rat) KCKCKECTYPRPLPS T189
Y191-p
CKCKECtyPRPLPsD
Upstream
0 1
Treatment
  • FGF2
SPRY2 (human) CKCKECtyPRPLPsD Y191-p
SPRY2 (mouse) CKCKECTYPRPLPSD Y191
SPRY2 (rat) CKCKECTYPRPLPSD Y190
S197-p
tyPRPLPsDWICDKQ
Upstream
0 1
Treatment
  • FGF2
SPRY2 (human) tyPRPLPsDWICDKQ S197-p
SPRY2 (mouse) TYPRPLPSDWICDKQ S197
SPRY2 (rat) TYPRPLPSDWICDKQ S196
S208-p
CDKQCLCsAQNVIDy
0 1
SPRY2 (human) CDKQCLCsAQNVIDy S208-p
SPRY2 (mouse) CDKQCLCSAQNVIDY S208
SPRY2 (rat) CDKQCLCSAQNVIDY S207
Y215-p
sAQNVIDyGTCVCCV
0 1
SPRY2 (human) sAQNVIDyGTCVCCV Y215-p
SPRY2 (mouse) SAQNVIDYGTCVCCV Y215
SPRY2 (rat) SAQNVIDYGTCVCCV Y214
Y227-p
CCVKGLFyHCSNDDE
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, inhibited
  • phosphorylation
Effects on Biological Processes:
  • transcription, altered
Treatment
  • EGF
  • FGF2
SPRY2 (human) CCVKGLFyHCSNDDE Y227-p
SPRY2 (mouse) CCVKGLFYHCSNDDE Y227
SPRY2 (rat) CCVKGLFYHCSNDDE Y226
Y269-p
FLPCLWCyLPAKGCL
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, inhibited
  • phosphorylation
Effects on Biological Processes:
  • transcription, altered
Treatment
  • EGF
  • FGF2
SPRY2 (human) FLPCLWCyLPAKGCL Y269-p
SPRY2 (mouse) FLPCLWCYLPAKGCL Y269
SPRY2 (rat) FLPCLWCYLPAKGCL Y268
Y283-p
LKLCQGCyDRVNRPG
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, inhibited
  • phosphorylation
Effects on Biological Processes:
  • transcription, altered
Treatment
  • EGF
  • FGF2
SPRY2 (human) LKLCQGCyDRVNRPG Y283-p
SPRY2 (mouse) LKLCQGCYDRVNRPG Y283
SPRY2 (rat) LKLCQGCYDRVNRPG Y282
S296-p
PGCRCKNsNtVCCKV
0 1
SPRY2 (human) PGCRCKNsNtVCCKV S296-p
SPRY2 (mouse) PGCRCKNSNTVCCKV S296
SPRY2 (rat) PGCRCKNSNTVCCKV S295
T298-p
CRCKNsNtVCCKVPt
0 1
SPRY2 (human) CRCKNsNtVCCKVPt T298-p
SPRY2 (mouse) CRCKNSNTVCCKVPT T298
SPRY2 (rat) CRCKNSNTVCCKVPT T297
T305-p
tVCCKVPtVPPRNFE
0 1
SPRY2 (human) tVCCKVPtVPPRNFE T305-p
SPRY2 (mouse) TVCCKVPTVPPRNFE T305
SPRY2 (rat) TVCCKVPTVPPRNFE T304
K313-ub
VPPRNFEkPT_____
0 1
SPRY2 (human) VPPRNFEkPT_____ K313-ub
SPRY2 (mouse) VPPRNFEKPT_____ K313
SPRY2 (rat) VPPRNFEKPT_____ K312